Dilon Technologies

Wayne Forrest
Oct 26, 2008
2008 10 23 16 40 11 166 Dilon Thumb Mol 2008

(Booth 9149) Scintimammography developer Dilon Technologies will feature new products and services, including the GammaLoc device for gamma-guided localization and biopsy, at RSNA 2008.

2008 10 23 16 40 12 880 Dilon Mol 2008The system is designed for 3D localization of focal intensities when using molecular imaging agents. It's pending 510(k) clearance from the U.S. Food and Drug Administration.

Also on display will be the Dilon 6800 Access, a transportable, secure version of the original Dilon 6800 scintimammography system. The camera is designed for use in medical centers that may not have patient volumes high enough to justify a full-time system.

The Newport News, VA-based company also will detail its medical physics consulting services, as well as new partnerships with mammography information systems developer PenRad Technologies of Plymouth, MN, and portable-ultrasound technology developer Terason of Burlington, MA.

Dilon also will show its Dilon 6800 gamma camera, and the company will discuss its efforts to expand international distribution of the product.

Latest in Nuclear Medicine
Alzheimers Tau
Having a father with Alzheimer's could mean higher risk of the disease
April 9, 2025
China Flag
China limits exports of rare earth elements, targets CT x-ray tubes
April 4, 2025
Imaging Life Issue 20 now available
Sponsored
Imaging Life Issue 20 now available
April 1, 2025
Kidneys
Kidneys appear to tolerate Lu-177 treatments
December 19, 2024
Related Stories
Rsna
Market research reports
RSNA
2008 10 23 16 40 43 9 Siemens Thumb Mol 2008
Nuclear Medicine
Siemens Healthcare
2008 10 24 11 27 35 29 Philips Thumb Mol 2008
Nuclear Medicine
Philips Healthcare
Imaging Life Issue 20 now available
Sponsor Content
Imaging Life Issue 20 now available
More in Nuclear Medicine
Having a father with Alzheimer's could mean higher risk of the disease
By Kate Madden Yee
Having a father with Alzheimer's may be tied to a greater spread of the tau protein in the brain, researchers have reported.
April 9, 2025
Alzheimers Tau
China limits exports of rare earth elements, targets CT x-ray tubes
By Erik L. Ridley
China's Ministry of Commerce has announced export controls for several rare earth elements and launched investigations of imported CT x-ray tubes.
April 4, 2025
China Flag
IAEA touts radionuclide development activities
By Will Morton
The IAEA has highlighted its worldwide activities to meet increasing demands for alpha-emitting radionuclides for use in Targeted Alpha Therapy.
March 18, 2025
Isotopes1
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
How effective is Pluvicto in a ‘real-world’ setting?
By Will Morton
Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.
September 20, 2024
Prostate
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
The rise of theranostics: Part 3 -- What is a theranostics center?
By Liz Carey
For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.
June 3, 2024
Part3 Riseof Thernaostics Cover
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
Page 1 of 436
Next Page